Description: NOSO-502 is the first clinical candidate in the novel antibiotic class called Odilhorhabdins, inhibiting the bacterial ribosome with a new mechanism of action.

Mode of Action (MoA): Inhibition bacterial ribosome

Description: Boosting Ethionamide efficacy and lowering the dose with small molecule transcriptional modulators to overcome multi-drug resistant tuberculosis infections and define a new place for Ethionamide in 1st-line tuberculosis treatments.

Mode of Action (MoA): Transcriptional modulator

Description: Demonstrating penetration of gepotidacin in tonsillar and prostate tissues.

Mode of Action (MoA): Topoisomerase type II inhibitor

Description: Molecule targeting cholesterol catabolism of mycobacteria.

Mode of Action (MoA): Cholesterol catabolism of mycobacteria

Description: Compound targeting Mycobacterium tuberculosis tryptophan synthase, enzyme that catalyses the final two steps in the biosynthesis of tryptophan.

Mode of Action (MoA): Mycobacterium tuberculosis tryptophan synthase

Description: Compounds targeting energy metabolism (electron chain transport).

Mode of Action (MoA): Energy metabolism

Description: Compound targeting lysine transfer RNA synthetase, which is an essential gene as assessed by transposon mutagenesis.

Mode of Action: Lysine transfer RNA synthase

Description: Mycobacterial membrane protein Large 3 (Mmpl3) compounds with potent in vitro inhibitory and bactericidal activity against Mycobacterium tuberculosis.

Mode of Action: Mmpl3

Natural product analogs active against Mycobacterium tuberculosis.

Description: Piperazinobenzothiazinone derivative as anti-mycobacterial compound that targets and covalently inhibits the enzyme Decaprenyl-phosphoryl-ribose 2'-epimerase (DprE1).

Mode of Action (MoA): DprE1

Description: Lead optimisation program on BC1 inhibitors.

Mode of Action (MoA): BC1

Description: Mycothione reductase (Mtr) target exploration.

Mode of Action (MoA): Mtr

Progress novel assets (one First-in-human start) for Non-Tubercular Mycobacterium (NTM) that may act synergistically with Bedaquiline and cytochrome bc Drugs.

Description: A first-in-class investigational antitubercular agent which is being developed for the treatment of tuberculosis as part of a future combination regimen. New MoA/not regulatory approved product with this MoA.  Suppresses protein synthesis in Mycobacterium tuberculosis (Mtb) by inhibiting the enzyme leucyl t-RNA synthetase (LeuRS).

Mode of Action (MoA): LeuRS

Description: A first-in-class investigational antitubercular agent which is being developed for the treatment of tuberculosis as part of a future combination regimen. New MoA/not regulatory approved product with this MoA. BTZ-043 inhibits an enzyme (BTZ-043) with is essential for cell wall synthesis in mycobacteria tuberculosis.

Mode of Action (MoA): Cell wall synthesis